CRISPR Therapeutics AG (CRSP)

The fundamental economics of CRISPR Therapeutics AG currently reflect a distressed capital allocation profile, evidenced by an ROIC of -24.8% and a Piotroski F-Score of 2/9, signaling severe deterioration in financial health relative to the typical nine-point scale used for assessing quality. Through a DuPont lens, negative returns on invested capital suggest that operating leverage or asset turnover is failing to generate earnings before interest and taxes, rather than indicating an issue with financial leverage alone. This weak profitability factor (RMW) of -1.783 further confirms the company's inability to convert revenue into net income efficiently, while the low F-Score implies potential issues in fundamental areas such as profit margins or asset quality compared to peers.

Valuation metrics present a complex divergence between historical norms and sector benchmarks; although the stock trades at a P/E multiple significantly below the healthcare sector average of 37.0x, this discount may reflect market skepticism regarding future cash flow generation rather than undervaluation given the negative ROIC. Any discounted cash flow analysis would likely yield a depressed fair value due to the implied growth assumptions required to overcome current losses and the lack of profitability traction. Consequently, the low valuation appears driven by fundamental operational struggles rather than an attractive entry point relative to intrinsic worth derived from sustainable earnings power.

Risk-reward dynamics are further complicated by conflicting factor exposures; while the stock exhibits a strong positive Fama-French alpha of 17.94% annually, suggesting outperformance on a risk-adjusted basis over time, this is counterbalanced by a significant negative value factor (HML) of -0.651, indicating a heavy growth tilt that leaves it vulnerable during market rotations toward value. Compounding these macro factors, insider activity over the last 90 days shows net selling totaling $12,285,734, which often precedes downward pressure or signals management's lack of confidence in near-term prospects despite the historical alpha generation.